MiMedx Group Inc
MDXG
查看详细走势图
5.150USD
+0.120+2.39%
收盘 02/06, 16:00（美东）报价延迟15分钟
762.59M总市值
18.61市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.39%
5天
+0.78%
1月
-20.03%
6月
-27.57%
今年开始到现在
-23.93%
1年
-38.03%
查看详细走势图
TradingKey MiMedx Group Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
MiMedx Group Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名40/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价10.40。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
MiMedx Group Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
MiMedx Group Inc亮点
亮点风险
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
业绩高增长
公司营业收入稳步增长，连续3年增长30.26%
估值合理
公司最新PE估值18.61，处于3年历史合理位
机构减仓
最新机构持股106.79M股，环比减少2.74%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值15.75K
分析师目标
根据
5
位分析师
买入
评级
10.400
目标均价
+103.52%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
MiMedx Group Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
MiMedx Group Inc简介
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
公司代码MDXG
公司MiMedx Group Inc
CEOCapper (Joseph H)
网址https://mimedx.com/
相关品种
